From the WAVES Growth OS

D3 helps founder-led life sciences, pharma, and med device companies grow.

If you’re building a $1M–$50M founder-led B2B company in life sciences, SaaS, software, pharmaceutical, or medical device and you’re ready for an operating layer that compounds, we’d love to talk. See how WAVES works →  |  Take the WAVES Kompass

Send us a text

Jesse Mendelsohn and Michael Grosberg from Model N discuss why U.S. pricing complexity is spreading globally, the collapse of the PBM rebate model, what's really driving the pharmaceutical manufacturing boom, and why direct-to-consumer discount programs won't solve America's drug access problem.

00:00 Introduction to Life Science Success Podcast
00:34 Pressing Issues in Pharmaceutical Manufacturing
00:51 Introducing the Experts from Model N
03:08 Understanding International Reference Pricing
04:14 Impact of US Pricing on Global Drug Launches
09:26 Challenges with Pharmacy Benefit Managers
16:29 Domestic Manufacturing Boom in Pharmaceuticals
23:08 AI in Drug Discovery and Personalized Medicine
29:03 Access and Policy Discussion
30:01 Direct to Consumer Pricing
31:32 TrumpRx Overview
33:11 Compliance Challenges
38:30 Pharmaceutical Revenue Management
41:38 AI in Life Sciences
48:35 Future of Life Sciences
50:45 Concerns and Challenges
53:52 Excitement in Current Work
55:54 Conclusion and Final Thoughts